ESS Tech receives NYSE notice of minimum bid-price deficiency, has six months to cure
ESS Tech received written notice from the New York Stock Exchange on June 9, 2026, that the company failed to satisfy the continued listing standard under NYSE Rule 802.01C because its average closing share price was less than $1.00 per share over a consecutive 30 trading-day period. As of June 8, 2026, the 30 trading-day average closing price was $0.98 per share. The notice is a deficiency, not a delisting determination, and does not currently affect the company's listing or trading. ESS Tech has six months from receipt of the notice to regain compliance and intends to notify the NYSE of its cure plan within 10 business days; the company is considering options including a potential reverse stock split.
Key facts
- 30 trading-day average closing share price as of June 8, 2026: $0.98 per share
- NYSE Rule 802.01C minimum requirement: closing share price of at least $1.00 and average closing share price of at least $1.00 over 30 trading-day period
- Six-month cure period begins June 9, 2026
- Company must notify NYSE of intent to cure within 10 business days of receipt
- Compliance can be achieved on the last trading day of any calendar month during the cure period
- Company is considering a reverse stock split as a remedy option
- Stock continues to trade on NYSE during cure period
Why it matters
The deficiency notice creates a deadline for ESS Tech to restore its stock price or execute an alternative remedy such as a reverse stock split; failure to regain compliance within six months (or any extended period) could result in a delisting determination that would remove the company from the NYSE.
Share
Get the next chapter in your inbox — a Sentinel watches this company and briefs the next material filing the moment it lands.
Derived from 8-K filed 2026-06-15. Not investment advice. View the source filing on SEC.gov →